KLI

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Metadata Downloads
Abstract
Background: In East Asia, S-1 plus cisplatin (SP) is one of the standard first-line chemotherapy regimens for metastatic or recurrent gastric cancer (MRGC). Oxaliplatin is generally less toxic and more convenient to administer than cisplatin. Patients and methods: This was a multicenter, phase III study assessing whether S-1/oxaliplatin (SOX) was non-inferior/superior to SP in terms of progression-free survival (PFS). Patients with MRGC were randomized 1:1 to receive either SOX (S-1 80?mg/m
Author(s)
강윤구박숙련오호석유민희조재철Bong-Gun SeoByung-Ho NamHye Sook HanHyo Rak LeeIk Joo ChungJin Won KimKeun-Wook LeeKyung Hee LeeSang Hee ChoYoung Iee Park
Issued Date
2021
Type
Article
Keyword
Abdominal SurgeryAntimitotic agentsAntineoplastic agentsCancerCancer ResearchChemotherapyClinical trialsDrug therapyDrug therapyCombinationGastroenterologyMedicineMedicine & Public HealthOncologyOriginal ArticleProduct developmentStomach cancerSurgical Oncology
DOI
10.1007/s10120-020-01101-4
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7902
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_gale_infotracacademiconefile_A647786748&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Multicenter%20phase%20III%20trial%20of%20S-1%20and%20cisplatin%20versus%20S-1%20and%20oxaliplatin%20combination%20chemotherapy%20for%20first-line%20treatment%20of%20advanced%20gastric%20cancer%20(SOPP%20trial)&offset=0&pcAvailability=true
Publisher
GASTRIC CANCER
Location
일본
Language
영어
ISSN
1436-3291
Citation Volume
24
Citation Number
1
Citation Start Page
156
Citation End Page
167
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.